Patients and doctors in emerging markets want more than just high-quality medicines, says Andrew Lane, executive vice president of Abbott's Established Pharmaceuticals Division (EPD) that sells branded generic drugs solely in fast-growing emerging countries. Andrew's discussion of how companies can do more appears in the publication eyeforpharma.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
FOLLOW ABBOTT